Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01613768 · ClinicalTrials.gov registry record · Phase 2
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
A Phase 2 study of Recurrent Salivary Gland Cancer and Stage IVA Salivary Gland Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT01613768 is a Phase 2 study of Recurrent Salivary Gland Cancer and Stage IVA Salivary Gland Cancer that has completed, run by University of Washington. The registered enrollment target is 29 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01613768, a Phase 2 study of Recurrent Salivary Gland Cancer and Stage IVA Salivary Gland Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.
Conditions Studied
Interventions
- DRUG eribulin mesylate
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-05-08 |
| Est. Completion | 2017-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01613768
The ClinicalTrials.gov registry entry for NCT01613768 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Recurrent Salivary Gland Cancer appearing as the primary indexed condition, and to 1 intervention - of which eribulin mesylate is the first listed.
NCT01613768 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01613768 about?
NCT01613768 is a clinical study titled "Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer". Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.
What is the current status of trial NCT01613768?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2012-05-08. Estimated completion is 2017-08-23.
What conditions does trial NCT01613768 study?
This clinical trial studies the following conditions: Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer.
What interventions are being tested in trial NCT01613768?
The interventions under investigation include: eribulin mesylate (DRUG).
Who is sponsoring clinical trial NCT01613768?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01613768 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Salivary Gland Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Salivary Gland Cancer
All registered trials for this condition
Stage IVA Salivary Gland Cancer
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.